Stockreport

Baudax Bio: Recro's Spin-Out Is A Buy At These Prices [Seeking Alpha]

Baudax Bio, Inc.  (BXRX) 
PDF Summary Baudax Bio is a recent spin-out of Recro Pharma's Acute Care Segment and is already preparing for Ajenso's PDUFA date on February 20th. If approved, Ajenso will [Read more]